Literature DB >> 19193637

Complex I is rate-limiting for oxygen consumption in the nerve terminal.

Jayne E Telford1, Seán M Kilbride, Gavin P Davey.   

Abstract

Metabolic control analysis was used to determine the spread of control exerted by the electron transport chain complexes over oxygen consumption rates in the nerve terminal. Oxygen consumption rates and electron transport chain complex activities were titrated with appropriate inhibitors to determine the flux control coefficients and the inhibition thresholds in rat brain synaptosomes. The flux control coefficients for complex I, complex II/III, complex III, and complex IV were found to be 0.30 +/- 0.07, 0.20 +/- 0.03, 0.20 +/- 0.05, and 0.08 +/- 0.05, respectively. Inhibition thresholds for complex I, complex II/III, complex III, and complex IV activities were determined to be approximately 10, approximately 30, approximately 35, and 50-65%, respectively, before major changes in oxygen consumption rates were observed. These results indicate that, of the electron transport chain components, complex I exerts a high level of control over synaptosomal bioenergetics, suggesting that complex I deficiencies that are present in neurodegenerative disorders, such as Parkinson disease, are sufficient to compromise oxygen consumption in the synaptosomal model of the nerve terminal.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193637      PMCID: PMC2666560          DOI: 10.1074/jbc.M809101200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  In vivo control of respiration by cytochrome c oxidase in human cells.

Authors:  G Villani; G Attardi
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

2.  Threshold effect and tissue specificity. Implication for mitochondrial cytopathies.

Authors:  R Rossignol; M Malgat; J P Mazat; T Letellier
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

3.  High frequency of mitochondrial complex I mutations in Parkinson's disease and aging.

Authors:  Rafal Smigrodzki; Janice Parks; W Davis Parker
Journal:  Neurobiol Aging       Date:  2004 Nov-Dec       Impact factor: 4.673

4.  Partial inhibition of complex I activity increases Ca-independent glutamate release rates from depolarized synaptosomes.

Authors:  Seán M Kilbride; Jayne E Telford; Keith F Tipton; Gavin P Davey
Journal:  J Neurochem       Date:  2008-04-28       Impact factor: 5.372

5.  Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals.

Authors:  Ildikó Sipos; Laszlo Tretter; Vera Adam-Vizi
Journal:  J Neurochem       Date:  2003-01       Impact factor: 5.372

6.  Preparation and properties of mitochondria derived from synaptosomes.

Authors:  J C Lai; J B Clark
Journal:  Biochem J       Date:  1976-02-15       Impact factor: 3.857

7.  A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients.

Authors:  I Maurer; S Zierz; H J Möller
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

8.  A linear steady-state treatment of enzymatic chains. General properties, control and effector strength.

Authors:  R Heinrich; T A Rapoport
Journal:  Eur J Biochem       Date:  1974-02-15

9.  The control of flux.

Authors:  H Kacser; J A Burns
Journal:  Symp Soc Exp Biol       Date:  1973

10.  Oxidative phosphorylation by in situ synaptosomal mitochondria from whole brain of young and old rats.

Authors:  O J P Joyce; M K Farmer; K F Tipton; R K Porter
Journal:  J Neurochem       Date:  2003-08       Impact factor: 5.372

View more
  32 in total

Review 1.  The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease.

Authors:  Aris A Polyzos; Cynthia T McMurray
Journal:  Mech Ageing Dev       Date:  2016-09-12       Impact factor: 5.432

2.  NDUFV2 pseudogene (NDUFV2P1) contributes to mitochondrial complex I deficits in schizophrenia.

Authors:  Oded Bergman; Rachel Karry; Jumana Milhem; Dorit Ben-Shachar
Journal:  Mol Psychiatry       Date:  2018-12-10       Impact factor: 15.992

3.  Control of respiration by cytochrome c oxidase in intact cells: role of the membrane potential.

Authors:  Maria Elena Dalmonte; Elena Forte; Maria Luisa Genova; Alessandro Giuffrè; Paolo Sarti; Giorgio Lenaz
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

Review 4.  Mitochondrial Oxidative Phosphorylation System (OXPHOS) Deficits in Schizophrenia: Possible Interactions with Cellular Processes.

Authors:  Oded Bergman; Dorit Ben-Shachar
Journal:  Can J Psychiatry       Date:  2016-08       Impact factor: 4.356

Review 5.  The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson's disease and in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2019-12-17       Impact factor: 3.575

6.  The rate of oxygen utilization by cells.

Authors:  Brett A Wagner; Sujatha Venkataraman; Garry R Buettner
Journal:  Free Radic Biol Med       Date:  2011-05-27       Impact factor: 7.376

7.  Convergent patterns of evolution of mitochondrial oxidative phosphorylation (OXPHOS) genes in electric fishes.

Authors:  Ahmed A Elbassiouny; Nathan R Lovejoy; Belinda S W Chang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-12-02       Impact factor: 6.237

8.  Decylubiquinone increases mitochondrial function in synaptosomes.

Authors:  Jayne E Telford; Seán M Kilbride; Gavin P Davey
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

Review 9.  AIF, reactive oxygen species, and neurodegeneration: a "complex" problem.

Authors:  Brian M Polster
Journal:  Neurochem Int       Date:  2012-12-12       Impact factor: 3.921

Review 10.  Brain Energy Deficit as a Source of Oxidative Stress in Migraine: A Molecular Basis for Migraine Susceptibility.

Authors:  Jonathan M Borkum
Journal:  Neurochem Res       Date:  2021-04-30       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.